Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Can a smartphone app help breast cancer patients stay on track with Life-Saving pills?

NCT ID NCT05488145

First seen Apr 19, 2026 · Last updated Jun 19, 2026 · Updated 10 times

Summary

This study tested whether a web-based app could help women with early-stage hormone-positive breast cancer take their daily hormone therapy more consistently. Many patients stop taking these pills due to side effects or lack of support, which raises the risk of cancer returning. The app provided reminders, educational videos, and direct contact with nurses to help patients stay on track. The study enrolled 21 participants and focused on whether patients found the app easy to use and whether it improved their medication adherence.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANATOMIC STAGE I BREAST CANCER AJCC V8 are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Emory Johns Creek Hospital

    Johns Creek, Georgia, 30097, United States

  • Emory Saint Joseph's Hospital

    Atlanta, Georgia, 30342, United States

  • Emory University Hospital Midtown

    Atlanta, Georgia, 30308, United States

  • Emory University Hospital/Winship Cancer Institute

    Atlanta, Georgia, 30322, United States

Conditions

The condition(s) this trial relates to.

breast cancer Her2-receptor negative breast cancer hormone receptor-positive breast cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.